Blog
RSS FeedPosted by Michael Wonder on 14 Sep 2021
Trodelvy approved by the TGA
14 September 2021 - Sacituzumab govitecan is a new treatment option for adult patients with unresectable locally advanced or metastatic triple negative ...
Posted by Michael Wonder on 14 Sep 2021
New therapy to treat advanced small cell lung cancer approved for Australian patients
14 September 2021 - Zepzelca approval granted under a provisional regulatory pathway. ...
Posted by Michael Wonder on 13 Sep 2021
Joint statement of support for an Australian Patent Box
13 September 2021 - Australia’s health innovators support the introduction of a Patent Box, and we welcome this initiative by the ...
Posted by Michael Wonder on 13 Sep 2021
Trodelvy approved following heroic efforts of breast cancer sufferer Alison Day
12 September 2021 - A dying woman’s selfless campaign will give Australian women battling a rare aggressive form of breast cancer ...
Posted by Michael Wonder on 07 Sep 2021
TGA approves new cancer medicine
7 September 2021 - Luspatercept (Reblozyl) is used to treat patients with certain transfusion-dependent anaemias. ...
Posted by Michael Wonder on 23 Aug 2021
TGA grants provisional determination to Celltrion Healthcare's anti-viral COVID-19 treatment regdanvimab
23 August 2021 - On 20 August 2021 the TGA granted provisional determination to Celltrion Healthcare in relation to regdanvimab. ...
Posted by Michael Wonder on 23 Aug 2021
TGA grants provisional determination to Roche combination COVID-19 treatment casirivimab and imdevimab (Ronapreve)
23 August 2021 - On 20 August 2021 the TGA granted provisional determination to Roche in relation to the combination ...
Posted by Michael Wonder on 22 Aug 2021
TGA approves new COVID-19 treatment for use in Australia
20 August 2021 - Australians with COVID-19 who are at risk of hospitalisation will now have access to an additional antibody ...
Posted by Michael Wonder on 20 Aug 2021
TGA provisionally approves GlaxoSmithKline's COVID-19 treatment sotrovimab (Xevudy)
20 August 2021 - Today, the Therapeutic Goods Administration granted provisional approval to GSK for its COVID-19 treatment - sotrovimab ...
Posted by Michael Wonder on 19 Aug 2021
TGA reduces timeframe for publishing adverse event reports
19 August 2021 - With strong public interest in adverse event reports relating to COVID-19 vaccinations, and improvements in our ...
Posted by Michael Wonder on 11 Aug 2021
New Alzheimer's drug aducanumab is dividing doctors and patients, as the TGA weighs up its risk-benefit profile
12 August 2021 - After a decades-long career as a biology teacher, John Rodgers applies the strict logic of a ...
Posted by Michael Wonder on 11 Aug 2021
TGA grants provisional determination to MSD's anti-viral COVID-19 treatment molnupiravir
10 August 2021 - On 9 August 2021 the Therapeutic Goods Administration granted provisional determination to MSD in relation to ...
Posted by Michael Wonder on 08 Aug 2021
New contraceptive pill: ‘safer’ Slinda pill with no blood clot risk, no periods available in Australia
8 August 2021 - A new generation contraceptive pill with no blood clot risks, that can be used by almost all ...
Posted by Michael Wonder on 08 Aug 2021
Additional COVID-19 treatment for Australia
8 August 2021 - The Australian Government has secured an initial shipment of over 7,700 doses of the novel monoclonal ...
Posted by Michael Wonder on 05 Aug 2021
Lupus drug will be ‘game changer’
5 August 2021 - The first targeted treatment for the debilitating auto-immune condition lupus could soon be available in Australia after ...